Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.

Tytuł:
Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
Autorzy:
Genoud V; Department of Oncology, University Hospital of Geneva, 1205 Geneva, Switzerland.; Center for Translational Research in Onco-Haematology, University of Geneva, 1205 Geneva, Switzerland.
Migliorini D; Department of Oncology, University Hospital of Geneva, 1205 Geneva, Switzerland.; Center for Translational Research in Onco-Haematology, University of Geneva, 1205 Geneva, Switzerland.; Brain Tumor and Immune Cell Engineering Laboratory, 1005 Lausanne, Switzerland.; Swiss Cancer Center Léman, 1205 Geneva, Switzerland.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 28; Vol. 22 (7). Date of Electronic Publication: 2021 Mar 28.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Brain Neoplasms/*immunology
Brain Neoplasms/*therapy
Glioblastoma/*immunology
Glioblastoma/*therapy
Immunotherapy/*methods
Cancer Vaccines/therapeutic use ; Central Nervous System/pathology ; Clinical Trials as Topic ; Humans ; Immune System ; Immunotherapy, Adoptive/methods ; Immunotherapy, Adoptive/trends ; Medical Oncology/methods ; Medical Oncology/trends ; Neoplasm Metastasis ; Oncolytic Viruses
References:
Cancer Cell. 2010 Jan 19;17(1):98-110. (PMID: 20129251)
Nat Genet. 2016 Jul;48(7):768-76. (PMID: 27270107)
Nature. 2018 May;557(7706):575-579. (PMID: 29769722)
Immunotherapy. 2019 Jun;11(8):677-689. (PMID: 31088236)
Cell Stem Cell. 2020 Jun 4;26(6):832-844.e6. (PMID: 32464096)
Lancet Oncol. 2021 Jan;22(1):118-131. (PMID: 33387490)
J Pathol. 2008 Sep;216(1):15-24. (PMID: 18553315)
Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. (PMID: 29500275)
Neuro Oncol. 2018 Sep 3;20(10):1283-1284. (PMID: 30137551)
Cancer Immunol Res. 2015 Apr;3(4):399-411. (PMID: 25678581)
Br J Cancer. 2014 May 13;110(10):2560-8. (PMID: 24691423)
Brain. 2016 May;139(Pt 5):1458-71. (PMID: 27020328)
Clin Cancer Res. 2017 Jan 1;23(1):124-136. (PMID: 27358487)
Cell Rep. 2019 Apr 16;27(3):971-986.e9. (PMID: 30995489)
Curr Opin Neurol. 2019 Dec;32(6):907-916. (PMID: 31577604)
Immunotherapy. 2018 Jul;10(9):779-786. (PMID: 30008259)
J Immunother Cancer. 2016 May 17;4:28. (PMID: 27190629)
Science. 2011 Mar 25;331(6024):1612-6. (PMID: 21436454)
BMC Cancer. 2020 Mar 12;20(1):198. (PMID: 32164579)
Clin Cancer Res. 2018 Feb 1;24(3):535-540. (PMID: 29158268)
Cell. 2020 Oct 1;183(1):126-142.e17. (PMID: 32961131)
J Vis Exp. 2019 Jun 28;(148):. (PMID: 31305527)
J Clin Invest. 2016 Aug 1;126(8):3036-52. (PMID: 27427982)
Mol Ther. 2013 Nov;21(11):2087-101. (PMID: 23939024)
Clin Exp Emerg Med. 2020 Jun;7(2):87-94. (PMID: 32635699)
Oncoimmunology. 2017 Nov 6;7(2):e1391973. (PMID: 29308321)
Oncoimmunology. 2018 Sep 6;7(12):e1500108. (PMID: 30524891)
J Exp Med. 2018 Jan 2;215(1):141-157. (PMID: 29203539)
J Clin Oncol. 2016 Jul 1;34(19):2206-11. (PMID: 27001570)
Cancer Cell. 2018 Apr 9;33(4):649-663.e4. (PMID: 29576375)
Cancers (Basel). 2020 Mar 22;12(3):. (PMID: 32235752)
N Engl J Med. 2005 Mar 10;352(10):997-1003. (PMID: 15758010)
J Immunother Cancer. 2017 Jul 18;5(1):53. (PMID: 28716061)
Acta Neurochir Suppl. 2005;95:389-92. (PMID: 16463887)
Nat Med. 2019 Mar;25(3):470-476. (PMID: 30742120)
Mol Ther. 2017 Feb 1;25(2):523-533. (PMID: 28153099)
Neuro Oncol. 2014 Oct;16 Suppl 8:viii20-5. (PMID: 25342601)
Adv Exp Med Biol. 2002;513:87-113. (PMID: 12575818)
Mol Ther. 2018 Jan 3;26(1):31-44. (PMID: 29103912)
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88. (PMID: 29117289)
Front Cell Dev Biol. 2019 Apr 24;7:60. (PMID: 31106200)
Nat Med. 2019 Mar;25(3):477-486. (PMID: 30742122)
Nat Med. 2020 May;26(5):712-719. (PMID: 32341579)
Brain. 2012 Apr;135(Pt 4):1042-54. (PMID: 22418738)
Neuro Oncol. 2011 Jan;13(1):132-42. (PMID: 20980335)
Science. 2020 Nov 27;370(6520):1099-1104. (PMID: 33243890)
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. (PMID: 33293629)
Cell Rep. 2017 Oct 31;21(5):1399-1410. (PMID: 29091775)
Neuro Oncol. 2020 Dec 18;22(12):1851-1861. (PMID: 32328662)
Neuro Oncol. 2019 Jul 11;21(7):923-933. (PMID: 30753611)
J Immunother. 2019 May;42(4):126-135. (PMID: 30882547)
Clin Epigenetics. 2019 Dec 5;11(1):185. (PMID: 31806041)
Cell Metab. 2016 Nov 8;24(5):649-650. (PMID: 27829133)
Clin Pharmacol Ther. 2010 May;87(5):586-92. (PMID: 20357763)
J Clin Oncol. 2018 Dec 10;36(35):3477-3484. (PMID: 30351999)
Neuro Oncol. 2015 Aug;17(8):1064-75. (PMID: 25355681)
J Transl Med. 2018 May 29;16(1):142. (PMID: 29843811)
Nat Med. 2013 Oct;19(10):1264-72. (PMID: 24056773)
PLoS One. 2012;7(2):e31046. (PMID: 22383993)
Exp Mol Pathol. 2011 Aug;91(1):440-6. (PMID: 21565182)
J Immunother Cancer. 2018 Oct 3;6(1):102. (PMID: 30285902)
Neuro Oncol. 2016 Dec;18(12):1601-1609. (PMID: 27407134)
Science. 2014 Jun 20;344(6190):1396-401. (PMID: 24925914)
Nat Commun. 2017 Jun 09;8:15618. (PMID: 28598415)
J Cancer Sci Clin Ther. 2021;5(2):210-220. (PMID: 35601813)
Nat Immunol. 2014 Oct;15(10):920-8. (PMID: 25194421)
J Immunother Cancer. 2018 Jun 11;6(1):51. (PMID: 29891009)
N Engl J Med. 2017 Nov 16;377(20):1954-1963. (PMID: 29141164)
Nat Rev Cancer. 2020 Jan;20(1):26-41. (PMID: 31601988)
Cell. 2020 Jun 25;181(7):1643-1660.e17. (PMID: 32470396)
Nature. 2019 Jan;565(7738):240-245. (PMID: 30568303)
Int J Mol Sci. 2020 Oct 09;21(20):. (PMID: 33050329)
Science. 2016 Mar 25;351(6280):1463-9. (PMID: 26940869)
Trends Immunol. 2002 Nov;23(11):549-55. (PMID: 12401408)
Clin Cancer Res. 2013 Mar 1;19(5):1035-43. (PMID: 23460534)
J Hematol Oncol. 2019 Nov 29;12(1):128. (PMID: 31783889)
Acta Neuropathol. 1987;74(3):269-77. (PMID: 3314311)
Nat Cancer. 2021 Jan;2(1):83-97. (PMID: 35121889)
Nature. 2015 Jul 16;523(7560):337-41. (PMID: 26030524)
Medicine (Baltimore). 2017 Nov;96(44):e8280. (PMID: 29095257)
Neuro Oncol. 2016 Mar;18(3):303-5. (PMID: 26917587)
Immunol Rev. 2006 Oct;213:48-65. (PMID: 16972896)
Neurooncol Pract. 2020 Jul 16;8(1):18-30. (PMID: 33664966)
Nature. 2020 Apr;580(7804):517-523. (PMID: 32322066)
Immunity. 2005 Feb;22(2):175-84. (PMID: 15723806)
Neuro Oncol. 2016 Apr;18(4):557-64. (PMID: 26449250)
Cancer Treat Rev. 2020 Jul;87:102029. (PMID: 32408220)
J Neurooncol. 2007 Jun;83(2):121-31. (PMID: 17077937)
Sci Transl Med. 2017 Mar 15;9(381):. (PMID: 28298418)
Sci Transl Med. 2017 Jul 19;9(399):. (PMID: 28724573)
Science. 2015 Apr 3;348(6230):69-74. (PMID: 25838375)
Clin Cancer Res. 2013 Sep 15;19(18):4951-60. (PMID: 23864165)
Lancet. 2019 Feb 16;393(10172):678-688. (PMID: 30782343)
Cell. 2021 Mar 4;184(5):1281-1298.e26. (PMID: 33592174)
Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059)
Cancer Lett. 2020 Jun 28;480:24-28. (PMID: 32229189)
Cancer. 2019 Aug 1;125(15):2561-2569. (PMID: 31012963)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Transl Oncol. 2009 May;2(2):89-95. (PMID: 19412424)
J Clin Oncol. 2018 May 10;36(14):1419-1427. (PMID: 29432077)
JAMA. 2017 Dec 19;318(23):2306-2316. (PMID: 29260225)
J Immunol. 2008 Jun 15;180(12):8434-43. (PMID: 18523311)
Cancer Treat Rev. 2019 Nov;80:101896. (PMID: 31541850)
Neuro Oncol. 2016 Aug;18(8):1146-56. (PMID: 26902851)
J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33335026)
Lancet Oncol. 2017 Oct;18(10):1373-1385. (PMID: 28844499)
Nat Immunol. 2020 Feb;21(2):120-134. (PMID: 31873291)
J Clin Oncol. 2013 Nov 10;31(32):4085-91. (PMID: 24101040)
Oncoimmunology. 2018 Sep 5;7(12):e1501137. (PMID: 30524896)
J Clin Oncol. 2006 Jun 1;24(16):2563-9. (PMID: 16735709)
Cancers (Basel). 2019 Oct 15;11(10):. (PMID: 31618934)
N Engl J Med. 2018 Jul 12;379(2):150-161. (PMID: 29943666)
Cancer Cell. 2019 Nov 11;36(5):471-482. (PMID: 31715131)
Neuron. 2018 Oct 24;100(2):375-388. (PMID: 30359603)
Cancer Cell. 2019 Jun 10;35(6):868-884.e6. (PMID: 31185211)
Brain. 2017 Jun 1;140(6):1548-1560. (PMID: 28334886)
Immunity. 2019 May 21;50(5):1317-1334.e10. (PMID: 30979687)
J Immunol. 1985 Feb;134(2):1003-9. (PMID: 3871205)
Leukemia. 2012 Dec;26(12):2538-45. (PMID: 22648449)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Oncologist. 2020 Jul;25(7):e1109-e1116. (PMID: 32272491)
Immunol Rev. 2011 May;241(1):63-76. (PMID: 21488890)
Contributed Indexing:
Keywords: clinical trials; glioblastoma; immunotherapy
Substance Nomenclature:
0 (Cancer Vaccines)
Entry Date(s):
Date Created: 20210403 Date Completed: 20210708 Latest Revision: 20231111
Update Code:
20240104
PubMed Central ID:
PMC8036548
DOI:
10.3390/ijms22073493
PMID:
33800593
Czasopismo naukowe
Glioblastoma is the most frequent primary neoplasm of the central nervous system and still suffers from very poor therapeutic impact. No clear improvements over current standard of care have been made in the last decade. For other cancers, but also for brain metastasis, which harbors a very distinct biology from glioblastoma, immunotherapy has already proven its efficacy. Efforts have been pursued to allow glioblastoma patients to benefit from these new approaches, but the road is still long for broad application. Here, we aim to review key glioblastoma immune related characteristics, current immunotherapeutic strategies being explored, their potential caveats, and future directions.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies